XBiotech

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.

Our mission is to pioneer marvels of science, transforming healthcare for people around the world.

We are devoted to unlocking the power of true human antibodies and discovering revolutionary therapies worldwide. By investing in science and the aspects of human life that define the world, we are changing the future of medicine.

XBiotech was recognized by FierceBiotech as one of Fierce's Top 15 Private Biotechs in 2014 and chosen as a 'Standout Company' by BioWorld in 2014, among other awards. In 2017, XBiotech was named to the 2017 Forbes Small Giants list.